Laura Akright
Schertz, TXNPI 1568548204
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 284 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 10.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,117 and has fallen 94.1% since, to $125 in 2024.
Across 284 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$645
- Novo Nordisk$641
- Amgen$625
- AstraZeneca$561
- Sanofi-aventis U.S. LLC$368
- Dexcom, Inc.$339
- plus $3K from 23 others
Across 4,990 payments — averaging $498.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$1.1M
- Pfizer$452K
- AbbVie$219K
- Sanofi US Services Inc.$213K
- Regeneron$152K
- Genentech, Inc.$90K
- plus $269K from 8 others
What the payments were for
- Food & beverage$5,912100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 33 | $645 |
| Novo Nordisk | 34 | $641 |
| Amgen(2 entities) | 22 | $625 |
| AstraZeneca(2 entities) | 27 | $561 |
| Sanofi-aventis U.S. LLC | 17 | $368 |
| Dexcom, Inc. | 9 | $339 |
| Johnson & Johnson | 15 | $269 |
| Regeneron | 2 | $257 |
| AbbVie | 14 | $249 |
| Lilly USA, LLC | 14 | $219 |
| Xeris Pharmaceuticals, Inc. | 5 | $209 |
| Currax Pharmaceuticals LLC | 21 | $200 |
| Zealand Pharma US, Inc. | 9 | $199 |
| Insulet Corporation | 15 | $191 |
| Valeritas, Inc. | 9 | $163 |
| Radius Health, Inc. | 2 | $139 |
| Medtronic(2 entities) | 8 | $137 |
| Boehringer Ingelheim | 7 | $125 |
| IBSA Pharma Inc. | 7 | $102 |
| Merck | 2 | $70 |
| Corcept Therapeutics | 3 | $47 |
| Ultragenyx Pharmaceutical Inc. | 2 | $43 |
| Hologic Sales And Service, LLC | 1 | $25 |
| Bayer | 1 | $22 |
| Intuity Medical Inc | 1 | $18 |
| Cequr Corporation | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Nalpropion Pharmaceuticals LLC | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRALUENT$257
- DISEASE STATE$125
- DEXCOM G7 GSS (161)$125
- EVENITY$122
- FARXIGA$114
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 40 | $690 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.